Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2016 Aug;22(8):1357-1367. doi: 10.1016/j.bbmt.2016.03.022. Epub 2016 Mar 26.

Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies.

Author information

1
Department of Hematology, Centre Hospitalier, Le Mans, France. Electronic address: klaribi@ch-lemans.fr.
2
Department of Hematology, Centre Hospitalier, Le Mans, France.
3
Laboratory of Hematology, Centre Hospitalier, Le Mans, France.
4
Laboratory of Anathomopathology, Centre Hospitalier, Le Mans, France.
5
Clinical Research Center, Centre Hospitalier, Le Mans, France.
6
Department of Medicine, Pôle Sante Sud, Le Mans, France.

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with an aggressive clinical course. It is grouped with acute myeloid leukemia-related precursor neoplasms in the 2008 World Health Organization classification. Most patients with BPDCN have skin lesions at diagnosis and subsequent or simultaneous involvement of the bone marrow, peripheral blood, and lymph nodes. Patients usually respond to initial chemotherapy but often relapse. Stem cell transplantation may improve survival. This neoplasm is derived from precursors of plasmacytoid dendritic cells and is characterized by the coexpression of the immunophenotypic markers CD4, CD56, CD123, blood dendritic cell antigen-2, blood dendritic cell antigen-4, CD2AP, and lineage(-). Atypical immunophenotype expression may be present, making diagnosis difficult. BPDCN is often associated with a complex karyotype, frequent deletions of tumor suppressor genes, and mutations affecting either the DNA methylation or chromatin remodeling pathways. A better understanding of the etiology and pathophysiology of this neoplasm could open the way to new therapies targeting specific signaling pathways or involving epigenetics.

KEYWORDS:

Blastic plasmacytoid dendritic cell neoplasm; Cytogenetics; Diagnosis; Epidemiology; Immunophenotypic; Treatment

PMID:
27026248
DOI:
10.1016/j.bbmt.2016.03.022
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center